Li R, Sundi D, Zhang J, et al. - This study was intended to assess the complete response rate (CRR) and recurrence-free rate (RFR) applying bladder-sparing agents after BCG failure in order to provide a frame of reference for future clinical trial results. Researchers conducted a systematic review of clinical trials using bladder-sparing therapeutics for non-muscle-invasive-bladder cancer (NMIBC) recurring after intravesical BCG (PROSPERO CRD42019130553). They carried out to search MEDLINE, EMBASE, and Cochrane Library. From the bibliography search, relevant studies distinguished and conference abstracts were searched to complement the systematic review. They enrolled a sum of 42 studies utilizing 24 treatment options and consisting of 2254 patients for final analysis. The data revealed that, to date, bladder-sparing therapies achieved modest efficacy in patients with NMIBC after BCG. Outcomes from the recent research will provide as a frame of reference for emerging trial results in the BCG-unresponsive space.